The company claims that the use of generative AI in drug discovery has significantly reduced the time and cost typically associated with drug development. Traditional methods of drug discovery would have taken more than $400 million and up to six years, but with generative AI, Insilico reached the first phase of clinical trials in only two and a half years, at a fraction of the cost. The progress of INS018_055 serves as a proof-of-concept for Pharma.AI, Insilico's end-to-end AI-driven drug discovery platform, and sets a precedent for the potential of generative AI to accelerate drug discovery.
Key takeaways:
- Insilico Medicine, a biotech startup, has announced the progress of what it claims to be the first AI-generated and AI-discovered drug, INS018_055, which has now reached Phase II clinical trials.
- The drug was discovered and prioritized using biology AI, while the molecule was generated using generative chemistry AI, setting a precedent for generative AI in drug discovery.
- Traditional drug discovery methods would have taken more than $400 million and up to six years, but with generative AI, Insilico reached the first phase of clinical trials in only two and a half years, at a fraction of the cost.
- The company's achievement is seen as a breakthrough in efficiently discovering medicines from scratch by processing massive amounts of data through generative AI in chemistry and biology.